This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jean-Claude Reubi, MD

JAMA. 1987;257(23):3277.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Endocrine tumors of the gastrointestinal tract are relatively rare neoplasias that secrete large amounts of peptide hormones such as insulin, glucagon, gastrin, or vasoactive intestinal peptide (VIP).¹ These substances are usually responsible for the distinct clinical features observed in patients with such tumors, named specifically insulinomas, glucagonomas, gastrinomas, VIPomas, or carcinoids. Although most are relatively slow-growing tumors, they may lead in early stages to dramatic symptoms such as hypoglycemia, gastric ulcerations, or watery diarrhea. Unfortunately, they are often difficult to localize precisely at that stage.²

Somatostatin,³ a tetradecapeptide that inhibits peptide hormone release in various sites such as the pituitary, the pancreas, and the gastrointestinal tract, has been shown recently to have beneficial effects when given chronically in the form of a stable non-degradable octapeptide analogue (SMS 201-995) in such gastrointestinal endocrine tumors.^4,5 It is likely that its therapeutic effect is due in part to inhibition . . . [Full Text PDF of this Article]

Author Affiliations
Bern, Switzerland

Footnotes
Edited by Roxanne K. Young, Associate Editor.

Reprint requests to Sandoz Research Institute Berne Ltd, PO Box 2173, CH-3001 Bern, Switzerland (Dr Reubi).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?